Uh oh, I googled
Posted , 4 users are following.
My mum (62) has had some trouble with breathlessness for about 4 months now. Initially she was told she had adult onset asthma and given inhalers. They didn't work so they tried a different inhaler. Again, no luck so she was prescribed a 2 week course of high dose steroids. Again, no relief. She was sent for a chest xray. This was normal. Spiromtery results were good at 94% and peak flow meter was within normal range. She had a ct scan and complete blood work done and gets these results tomorrow, but in the mean time I have been googling and have totally freaked myself out that IPF could be the cause of this issue. She has developed a wheezy dry cough over the past couple of weeks. It doesn't produce anything and seems to come and go (I was with her for 3 hours the other day and didn't hear one cough). I know tomorrow will be here soon but I'm scared for her. Could she have IPF if chest xray and spirometry results were good? I'm sorry to totally self diagnose, I have awful health anxiety and cannot help myself. Thank you for your suggestions/comments/help.
0 likes, 3 replies
epictetus1939 kelly40356
Posted
Best wishes.
bob80691 kelly40356
Posted
Hi Kelly:
My initial response to you is coming the day you and your Mother get the CT Scam results so let's see what that says. Please come back to us and we'll go from there. And take a few deep breaths!!
adrienne35302 kelly40356
Posted
Pacheco Y, Douss T, Pujol B, Revol A, Vergnon JM, Biot N, Brune J, Perrin-Fayolle M.Abstract
Various anomalies of pulmonary surfactant have been described in relation to acute respiratory distress syndromes, hypersensitivity lung disease and pulmonary sarcoidosis. Phosphatidylcholine (PC) is the essential phospholipid component of pulmonary surfactant. Cytidine diphosphocholine (CDP-choline) is an essential intermediary in the biosynthesis of PC. The authors studied two groups of patients: one group consisted of diffuse interstitial pulmonary fibrosis and the other consisted of pulmonary sarcoidosis with parenchymal involvement. They observed quantitative and qualitative abnormalities of the phospholipid fractions of surfactant and more particularly of PC. The finding of a marked decrease in this phospholipid, especially in the cases of pulmonary fibrosis, justified the study of the therapeutic effects of CDP-choline. After one month of treatment with this substance, at a dose of 1 g I.M. per day, the PC fraction had returned to normal and, at the same time, there was an improvement in the PaO2 at rest and after exercise. Long term administration of CDP-choline appears to be valuable in the maintenance of the phospholipid equilibrium of pulmonary surfactant and in the improvement of the quality of alveolar gas exchange.